Grant: Collaborative Health Research Projects (NSERC partnered)
McGill University
$383,593.00
An Injectable Phosphate Releasing Bone Tissue Construct Encapsulating Adipose-Derived Stem Cells and Diphosphate Cleaving Enzymes to Promote Biomineralization in Critical Size Bone Defects
EF 2018-19
Résumé
Critical size bone defects (CSBD) are non-healing bone injuries that require a therapeutic intervention to induce bone formation. These injuries occur due to trauma, removal of tumors, developmental anomalies, and infections. Impaired bone healing, including delayed union or non-union, accounts for 150,000 to 200,000 hospitalizations in Canada generating a $12 to $18 B/y burden on the health care system. The current golden standard is to graft autologous bone from the patient's iliac crest onto the defect. The need to create a second surgical intervention increases the risk of post-surgical complications and wound infections, and requires longer hospitalization. An injectable therapeutic modality that can be administered using minimally invasive surgery will reduce risk of infection, time of hospitalization and surgical costs. We successfully demonstrated, that injectable chitosan sponges developed in our laboratory, are biocompatible, and completely biodegrade within 60 days. The addition of enzymes to the chitosan sponges provided a constant release of phosphate ions, which significantly increased biomineralization in pre-osteoblast MC3T3 cells. Further, a high encapsulation efficiency of osteogenic factors in the sponge and its controlled release over a period of 30 days could be achieved. The encapsulation of both MC3T3 and Adipose-Derived Stem Cells (ASCs) indicated the suitability of the scaffold for cells' survivability, proliferation and differentiation. Herein, we propose to investigate the sponge as a delivery system and as a 3D-scaffold for ASCs encapsulation, enzymes and osteogenic factors, and ultimately as a tissue construct for in vivo biomineralization in CSBD. To translate this promising technology platform to clinics, it is imperative to validate the sponge in relevant animal model of CSBD. This opportunity will be offered by our success in this CHRP proposal in partnership with industry and commercialization specialists involved in this proposal.
Programme
Collaborative Health Research Projects (NSERC partnered)
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
396468
Name
Tabrizian Maryam
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Natural Sciences and Engineering Research Council of Canada (NSERC)
Instname2
Musculoskeletal Health and Arthritis
Theme2
Biomedical
Prcname2
Collaborative Health Research Projects - NSERC Partnered
Projecttitle
An Injectable Phosphate Releasing Bone Tissue Construct Encapsulating Adipose-Derived Stem Cells and Diphosphate Cleaving Enzymes to Promote Biomineralization in Critical Size Bone Defects
Programtype2
Operating Grants
Orgnameinp2
McGill University
Cihramount2
$383,593
Cihrequipment2
$0
Programname2
Collaborative Health Research Projects (NSERC partnered)
Keyworddelim
Adipose-Derived Stem Cells (Ascs); Biomineralization; Cell Encapsulation; Chitosan; Critical Size Bone Defects; Guanosine 5'-Diphosphate Crosslinker; In Vitro/In Vivo Assessment; In-Situ Rapid Gellation; Phosphatase & Phosphatase Orphan 1 (Phospho1); Self-Contained Phosphate Ions Sponge
Abstract
Critical size bone defects (CSBD) are non-healing bone injuries that require a therapeutic intervention to induce bone formation. These injuries occur due to trauma, removal of tumors, developmental anomalies, and infections. Impaired bone healing, including delayed union or non-union, accounts for 150,000 to 200,000 hospitalizations in Canada generating a $12 to $18 B/y burden on the health care system. The current golden standard is to graft autologous bone from the patient's iliac crest onto the defect. The need to create a second surgical intervention increases the risk of post-surgical complications and wound infections, and requires longer hospitalization. An injectable therapeutic modality that can be administered using minimally invasive surgery will reduce risk of infection, time of hospitalization and surgical costs. We successfully demonstrated, that injectable chitosan sponges developed in our laboratory, are biocompatible, and completely biodegrade within 60 days. The addition of enzymes to the chitosan sponges provided a constant release of phosphate ions, which significantly increased biomineralization in pre-osteoblast MC3T3 cells. Further, a high encapsulation efficiency of osteogenic factors in the sponge and its controlled release over a period of 30 days could be achieved. The encapsulation of both MC3T3 and Adipose-Derived Stem Cells (ASCs) indicated the suitability of the scaffold for cells' survivability, proliferation and differentiation. Herein, we propose to investigate the sponge as a delivery system and as a 3D-scaffold for ASCs encapsulation, enzymes and osteogenic factors, and ultimately as a tissue construct for in vivo biomineralization in CSBD. To translate this promising technology platform to clinics, it is imperative to validate the sponge in relevant animal model of CSBD. This opportunity will be offered by our success in this CHRP proposal in partnership with industry and commercialization specialists involved in this proposal.
Competitiondate
201810
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Tabrizian, Maryam; Norton, Brent A; Murshed, Monzur
Approvedterm
3 ans 0 mois
Cihrcontribution2
Major Initiatives #2~ $383,593~ $0~